0001209191-20-018222.txt : 20200311
0001209191-20-018222.hdr.sgml : 20200311
20200311175533
ACCESSION NUMBER: 0001209191-20-018222
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200309
FILED AS OF DATE: 20200311
DATE AS OF CHANGE: 20200311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bright Rex
CENTRAL INDEX KEY: 0001327501
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38356
FILM NUMBER: 20706492
MAIL ADDRESS:
STREET 1: 5641 LAKE VISTA DRIVE
CITY: BONSALL
STATE: CA
ZIP: 92003
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Menlo Therapeutics Inc.
CENTRAL INDEX KEY: 0001566044
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453757789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 CARDINAL WAY, 2ND FLOOR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-486-1416
MAIL ADDRESS:
STREET 1: 200 CARDINAL WAY, 2ND FLOOR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics, Inc.
DATE OF NAME CHANGE: 20170728
FORMER COMPANY:
FORMER CONFORMED NAME: Tigercat Pharma, Inc.
DATE OF NAME CHANGE: 20130104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-09
0
0001566044
Menlo Therapeutics Inc.
MNLO
0001327501
Bright Rex
200 CARDINAL WAY, 2ND FLOOR
REDWOOD CITY
CA
94063
1
0
0
0
Stock Options
9.93
2020-03-09
4
A
0
15994
A
2020-03-09
2024-12-29
Common Stock
15994
15994
D
Stock Options
8.04
2020-03-09
4
A
0
12773
A
2027-07-12
Common Stock
12773
12773
D
Stock Options
8.54
2020-03-09
4
A
0
14778
A
2020-03-09
2028-05-08
Common Stock
14778
14778
D
Stock Options
4.50
2020-03-09
4
A
0
29271
A
2029-05-16
Common Stock
29271
29271
D
Stock Options
5.96
2020-03-09
4
A
0
22603
A
2030-02-27
Common Stock
22603
22603
D
Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020.
The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021.
The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020.
The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021.
/s/ Mutya Harsch, attorney-in-fact for Rex Bright
2020-03-11